Epioxa, the first FDA-approved epithelium-on cross-linking procedure, is now commercially available, according to a press ...

Please provide your email address to receive an email when new articles are posted on . Cross-linking is a resource-intensive procedure. Designating cross-linking “champions” will help improve and ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, ...

Patients in Somerset with keratoconus, an eye condition that causes blurred vision and sensitivity to light, can now access ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...